search-icon
Loading...

Guidance 2023

In the current financial year (2023), the Managing Board expects sales growth to continue and the adj. EBITDA margin to improve from the previous year. In the mid- to long-term, an adj. EBITDA margin in excess of 8% is anticipated.

20-30%
Non-Rx growth
€ 1.7-1.8 Bn
Total net sales
1.5-3%
Adjusted EBITDA margin
€ -20 to 20 M
Free cash flow